ASPIRING

Antiplatelet Secondary Prevention International Randomised study after INtracerebral haemorrhaGe

The Antiplatelet Secondary Prevention International Randomised study after INtracerebral haemorrhaGe (ASPIRING) aims to determine if antiplatelet monotherapy is of overall net benefit in reducing the incidence of major adverse cardiovascular events compared to avoiding antiplatelet therapy for adults with a history of stroke due to spontaneous intracerebral haemorrahge (ICH).

It is an investigator-led, multicentre, prospective, randomised, open-label, blinded outcome (PROBE), parallel-group clinical study.

ASPIRING is currently in a multicentre pilot phase in China and Australia. More information can be found on the ASPIRING website.

The ASPIRING main phase has been funded via the Global Cardiovascular Research Funders Forum Multinational Clinical Trials Initiative and other funders, to recruit 4,148 participants 2024-2028 in the following countries: